Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The gut microbiome (GM) has emerged in the last few years as a main character in several diseases. In pediatric oncological patients, GM has a role in promoting the disease, modulating the effectiveness of therapies, and determining the clinical outcomes. The therapeutic course for most pediatric cancer influences the GM due to dietary modifications and several administrated drugs, including chemotherapies, antibiotics and immunosuppressants. Interestingly, increasing evidence is uncovering a role of the GM on drug pharmacokinetics and pharmacodynamics, defining a bidirectional relationship. Indeed, the pediatric setting presents some contrasts with respect to the adult, since the GM undergoes a constant multifactorial evolution during childhood following external stimuli (such as diet modification during weaning). In this review, we aim to summarize the available evidence of pharmacomicrobiomics in pediatric oncology.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9740824 | PMC |
| http://dx.doi.org/10.3390/ijms232315387 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Principles and Terminology for Host-Microbiome-Drug Interactions.
Open Forum Infect Dis
May 2023
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
Interactions between the microbiome and medical therapies are distinct and bidirectional. The existing term "pharmacomicrobiomics" describes the effects of the microbiome on drug distribution, metabolism, efficacy, and toxicity. We propose that the term "pharmacoecology" be used to describe the effects that drugs and other medical interventions such as probiotics have on microbiome composition and function.
View Article and Find Full Text PDFPharmacomicrobiomics in IBD: Should We Select Treatments Based on Gut Microbes?
Gastroenterology
September 2023
Division of Pediatric Gastroenterology, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
Pharmacomicrobiomics in Pediatric Oncology: The Complex Interplay between Commonly Used Drugs and Gut Microbiome.
Int J Mol Sci
December 2022
Pediatric Oncology and Hematology "Lalla Seràgnoli", IRCCS Azienda Ospedaliero Universitaria di Bologna, 40138 Bologna, Italy.
The gut microbiome (GM) has emerged in the last few years as a main character in several diseases. In pediatric oncological patients, GM has a role in promoting the disease, modulating the effectiveness of therapies, and determining the clinical outcomes. The therapeutic course for most pediatric cancer influences the GM due to dietary modifications and several administrated drugs, including chemotherapies, antibiotics and immunosuppressants.
View Article and Find Full Text PDFReduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome after Hematopoietic Cell Transplantation.
Transplant Cell Ther
July 2022
Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN. Electronic address:
Mycophenolate mofetil (MMF) is an important immunosuppressant used after allogeneic hematopoietic cell transplantation (HCT). MMF has a narrow therapeutic index, and blood concentrations of mycophenolic acid (MPA), the active component of MMF, are highly variable. Low MPA concentrations are associated with the risk of graft-versus-host disease (GVHD), whereas high concentrations are associated with toxicity.
View Article and Find Full Text PDFThe impact of the host intestinal microbiome on carcinogenesis and the response to chemotherapy.
Future Oncol
November 2021
Department of Pediatrics/Division of Pediatric Hematology-Oncology, Dalhousie University/IWK Health Centre, Halifax, Canada.
Article Synopsis
- The microbiome includes all the microbes living in and on the human body, and an imbalance (dysbiosis) is linked to various health issues like inflammatory bowel disease, diabetes, and certain cancers.
- Changing the composition of the intestinal microbiome can be achieved through different methods, such as antibiotics, fecal transplantation, and probiotics.
- Research on the microbiome's influence on cancer treatment safety and effectiveness may lead to better treatment outcomes, highlighting its potential as an important target in future cancer therapies.